2-Acetylbutyrolactone (ABL), CAS No. 517-23-7, is a versatile, high-volume intermediate chemical that is indispensable in the synthesis of complex, high-value molecules across the life sciences sector. Its unique structure, featuring both a reactive acetyl group and a lactone ring, positions it as a vital precursor in the global production of essential nutrients and high-efficacy agrochemicals.
This product will be delivered within 1-3 business days.
The ABL industry is characterized by the following key features:
- Dual-Sector Dependency: The market is dominated by two primary, high-volume applications: the synthesis of Vitamin B1 (Thiamine) and the synthesis of the broad-spectrum fungicide Prothioconazole. This dual reliance provides market stability but links ABL demand directly to global agricultural trends and public health/nutrition policies.
- Complex Synthesis Route: The mainstream industrial production route for ABL involves the acylation of gamma-butyrolactone (GBL) with ethyl acetate in the presence of strong basic condensation agents, such as metal sodium, metal potassium, sodium ethoxide, or sodium amide (Claisen condensation). This requires specialized high-pressure/high-temperature reaction equipment and rigorous safety management.
- Geographic Production Concentration: The global market exhibits extreme concentration in the supply base, with China being the world's largest producer and consumer of ABL, serving both domestic and international markets for key derivatives. This creates significant supply chain concentration risk.
- Applications Driving ABL Demand
- Agrochemicals: Prothioconazole
- Role: ABL is a crucial intermediate in the synthesis of Prothioconazole, which is a novel, broad-spectrum triazole-thionebased fungicide originally introduced by Bayer in 2004.
- Market Impact: Prothioconazole is widely used to control numerous diseases in cereals, wheat, and legume crops. Its patent protection largely expired between 2015 and 2018 in major regions, leading to a massive increase in generic manufacturing, particularly in China. The product reached its peak sales of 855 million USD in 2014, making it a major, sustained source of demand for ABL.
- Other Agrochemicals: ABL is also used to synthesize Cycloate and Cyproconazole, which are essential for controlling fungal diseases.
- Pharmaceuticals: Vitamin B1 (Thiamine)
- Role: ABL is a primary intermediate in the complex synthesis pathway of Vitamin B1 hydrochloride and mononitrate, an essential nutrient involved in metabolism.
- Market Impact: Global demand is steady and essential, driven by the fortification of food, animal feed, and therapeutic use in human nutrition. Major global manufacturers include DSM-Firmenich, JiangXi Tianxin Pharmaceutical Co. Ltd., and Brother Enterprises Holding Co. Ltd.. This application provides highly stable, non-cyclical demand.
- Other Pharmaceuticals and Niche Agrochemicals:
- HIV/AIDS and Antipsychotics: ABL is converted into key intermediates like cyclopropyl methyl ketone, which is then used in the synthesis of anti-HIV drugs Efavirenz and Etravirine, and antipsychotic drugs such as Risperidone and Paliperidone.
- Other Drugs: ABL is involved in the synthesis of various drugs, including the antimalarial Chloroquine and Hydroxychloroquine (via the intermediate 5-Chloropentan-2-One), the anticonvulsant and sedative Clomethiazole hydrochloride, and the vasodilator Perhexiline maleate.
- Niche Agrochemicals: It is used in the synthesis of the fungicide Cyprodinil and the triazole fungicide Cyproconazole.
- Overview of Key Market Players and Capacities
- Zhejiang Realsun Chemical Co. Ltd. (China):
- Largest Producer: This is the largest producer in China and likely the world, with a reported capacity of 15,000 tons per year. This massive capacity dominates the global merchant market supply.
- JiangXi Tianxin Pharmaceutical Co. Ltd. (China):
- Integrated Producer: A major player in the Vitamin B1 market. The company completed an ABL production line in 2021 for its self-consumption in Vitamin B1 manufacturing, while also offering a portion for external sales.
- Aggressive Expansion: Its subsidiary, Ningxia Tianxin Pharmaceutical Co. Ltd., is currently developing a massive new ABL capacity project of 26,000 tons per year, indicating a strong commitment to vertical integration and future merchant market expansion.
- Synwill Co. Ltd. (China):
- Mid-Tier Player: Reports an existing capacity of 5,000 tons per year, making it a significant contributor to the global supply base.
- Xinxiang Ruicheng Technology Co. Ltd. (China):
- Mid-Tier Player with Expansion: Reports an existing capacity of 5,000 tons per year and has announced plans to substantially expand this capacity to 20,000 tons per year.
- Shaanxi Jinxinyi Chemical Technology Co. Ltd. (China):
- Expanding Player: Reports an existing capacity of 3,300 tons per year. The company announced a plan in 2024 to build an additional 3,500 tons per year capacity (currently not completed), with a long-term total capacity target of 18,000 tons per year.
- Zhejiang Rongkai Technology Development Co. Ltd. (China):
- Planned Entry: This company is planning to construct a new capacity of 16,000 tons per year, indicating a strong wave of planned new entrants into the market.
- DAICEL (Japan):
- Global Specialty Player: A major Japanese chemical company. While specific ABL capacity is not detailed, DAICEL is a renowned global supplier of acetyl-based chemicals and intermediates, positioning it as a potentially high-quality supplier, likely catering to non-Chinese markets.
- Value Chain Analysis
- Stage 1: Upstream Raw Materials
- gamma-Butyrolactone (GBL) and Ethyl Acetate: GBL is derived from 1,4-butanediol (BDO), linking ABL production costs to BDO and the broader petrochemical value chain. Ethyl acetate is also a major required co-reactant.
- Stage 2: ABL Intermediate Synthesis
- Key Process: Claisen condensation of GBL and Ethyl Acetate under strong base.
- Producers: The key Chinese manufacturers (Zhejiang Realsun, JiangXi Tianxin, Synwill) control this stage, commanding significant technical know-how in handling the specialized reaction conditions.
- Stage 3: Downstream Conversion (High-Value Synthesis)
- Prothioconazole Pathway: ABL is converted via a multi-step process into the final fungicide active ingredient. The majority of this conversion is undertaken by large agrochemical formulators (Bayer, Hailir Pesticides, Hefei Jiuyi Agriculture Development Co. Ltd.) or their contract manufacturers.
- Vitamin B1 Pathway: ABL is a key precursor incorporated into the B1 molecule. This is largely controlled by integrated pharmaceutical/nutritional giants (DSM-Firmenich, Brother Enterprises Holding Co. Ltd., JiangXi Tianxin).
- Stage 4: End-Market Consumption
- Agrochemicals: Sales of finished fungicide formulations to farmers globally.
- Nutritional/Pharmaceuticals: Sales of feed-grade and pharmaceutical-grade Vitamin B1, and finished drug products (Efavirenz, Hydroxychloroquine).
- Regional Market Trends
- Asia-Pacific (APAC)
- Production and Consumption Hub: China is the global epicenter for ABL production, driven by its integrated manufacturing capability for both generic agrochemicals and essential vitamins. The ongoing and planned capacity expansion exceeding 60,000 tons per year is almost entirely located here.
- Key Country Trends: China's market is driven by domestic consumption for B1 and Prothioconazole, and significant export volumes. India is a major consumer for its domestic agrochemical and pharmaceutical sectors, primarily importing ABL from China.
- Estimated CAGR: In the range of 2%-4% through 2030, supported by the continued essential demand for Vitamin B1 and global food security needs.
- North America and Europe
- High-Value Consumption and Regulatory Demand: These regions are major consumers of the final products (branded Prothioconazole, high-grade Vitamin B1, and pharmaceuticals). They rely on imports of the ABL intermediate but demand the highest quality and compliance standards.
- Trend: Demand is stable and driven by established markets for nutrition and agriculture. Companies often seek qualified suppliers that can demonstrate robust environmental and safety compliance.
- Estimated CAGR: In the range of 1%-3% through 2030, reflecting steady, stable growth for essential products.
- Latin America (LATAM) and MEA (Middle East & Africa)
- Emerging Consumption: These regions are growing markets for fungicides and nutritional supplements.
- Trend: Demand growth is linked to expanding agricultural production and improving nutritional standards, driving imports of final products and, indirectly, ABL demand.
- Estimated CAGR: In the range of 1%-2.5% through 2030.
- Opportunities and Challenges
- Opportunities
- Stable, Essential Demand Base: The dual reliance on Vitamin B1 (Nutrition) and Prothioconazole (Food Security) provides a highly stable demand floor, largely insulated from economic cycles. Global food production and health are non-negotiable markets.
- Niche Pharmaceutical Expansion: ABL's use in various complex, high-value drugs (Efavirenz, Risperidone, Hydroxychloroquine) allows producers to access high-margin, specialized segments, provided they can meet cGMP standards.
- Generic Prothioconazole Market: The patent expiration on Prothioconazole has opened the market to large-scale generic manufacturing, ensuring a massive, sustained volume requirement for ABL for the foreseeable future, especially in APAC.
- Vertical Integration: For ABL producers, the opportunity to vertically integrate into the production of high-value derivatives like Vitamin B1 (as JiangXi Tianxin is doing) or generic Prothioconazole intermediates provides a significant route for margin enhancement and supply security.
- Challenges
- Severe Capacity Oversupply Risk: The most immediate and critical challenge is the risk of severe overcapacity. Current Chinese capacity is already large (Zhejiang Realsun at 15,000 tpa), but the announced and planned expansions exceed 60,000 tons per year. This massive influx of new capacity is expected to place intense downward pressure on pricing, potentially pushing marginal producers out of the market and severely compressing industry-wide margins.
- Raw Material Dependency: The market is exposed to the price volatility and supply concentration of the upstream precursor gamma-Butyrolactone (GBL), which is itself linked to the petrochemical sector.
- Competition from Other Fungicides: While Prothioconazole is highly effective, it competes with newer or other established fungicides. Agrochemical formulators continuously seek cost-effective alternatives, posing a substitution risk.
- Geographic Concentration Risk: The overwhelming concentration of production in China exposes the global supply chain to political, regulatory, or environmental disruption in a single region, despite the current stable supply.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast 2-Acetylbutyrolactone Market in North America (2020-2030)
Chapter 10 Historical and Forecast 2-Acetylbutyrolactone Market in South America (2020-2030)
Chapter 11 Historical and Forecast 2-Acetylbutyrolactone Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast 2-Acetylbutyrolactone Market in Europe (2020-2030)
Chapter 13 Historical and Forecast 2-Acetylbutyrolactone Market in MEA (2020-2030)
Chapter 14 Summary for Global 2-Acetylbutyrolactone Market (2020-2025)
Chapter 15 Global 2-Acetylbutyrolactone Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- DAICEL
- Zhejiang Realsun Chemical Co. Ltd
- JiangXi Tianxin Pharmaceutical Co. Ltd.
- Zhejiang Rongkai Technology Development Co. Ltd.
- Synwill Co. Ltd.
- Shaanxi Jinxinyi Chemical Technology Co. Ltd
- Xinxiang Ruicheng Technology Co. Ltd.
